Age-related macular
degeneration —
what is happening
to your central vision
AMD is the most common cause of vision loss in people over 60. It doesn't cause complete blindness — but it can take away your ability to read, drive, and recognise faces. Here is what you need to know.
When people describe their AMD diagnosis, they often say the same thing: "My vision went blurry but I thought it was just my glasses." AMD is deceptive. It starts in the peripheral retina, works its way inward slowly, and by the time the central vision goes, the disease has usually been present for years.
This guide is published by Agaaz Ophthalmics — an Indian manufacturer of ophthalmic surgical products used in the surgeries and procedures that treat eye disease. We write these guides because patients deserve to understand what is happening inside their eyes, not just receive a diagnosis they can't interpret.
AMD is the leading cause of irreversible central vision loss in people over 60 in high-income countries — and it is rising rapidly across India, the Middle East (UAE, Saudi Arabia), Sub-Saharan Africa (Nigeria, South Africa, Kenya), and Southeast Asia (Philippines, Indonesia, Malaysia) as populations age. Understanding it is the first step to managing it.
AMD does not cause complete blindness. Peripheral (side) vision is almost always preserved. What AMD takes is central vision — the sharp, straight-ahead vision needed to read, drive, and recognise faces. Most people with AMD can still see well enough to move around independently, but reading, fine detail work, and recognising faces becomes progressively difficult without support.
What Is Macular Degeneration — and What Is the Macula?
The macula is a small, highly specialised area at the very centre of the retina — roughly 5mm in diameter. Despite its size, it is responsible for all your sharp, detailed central vision. When you read a word, look at a face, or thread a needle, you are using your macula. It contains the highest density of cone photoreceptors of anywhere in the retina.
Age-related macular degeneration (AMD) is a progressive disease in which the macula deteriorates over time. The "age-related" part matters — it is the most important risk factor. AMD rarely occurs under 55, but affects approximately 10% of people over 75 and up to 30% of those over 85.
The disease typically begins with the accumulation of waste deposits under the retinal pigment epithelium (RPE) — the layer of cells that nourishes and maintains the photoreceptors. These deposits are called drusen. Small drusen are normal with ageing. Large or numerous drusen signal early AMD and indicate the eye is struggling to clear its waste products efficiently.
AMD vs cataract — the difference many patients confuse: Both cause blurry vision, but they are completely different diseases. A cataract is a clouding of the eye's lens — it is surgically curable. AMD is a disease of the retina — it cannot be cured, only slowed or stabilised. Some patients have both simultaneously. If you have AMD and need cataract surgery, see the dedicated section later in this guide.
Dry AMD vs Wet AMD — The Critical Difference
AMD exists in two forms — dry and wet — and the distinction matters enormously for prognosis and treatment.
Wet AMD develops when abnormal new blood vessels — a process called choroidal neovascularisation (CNV) — grow under the macula. These vessels are fragile. They leak fluid and blood into the retina, causing rapid, severe vision loss. Any patient with dry AMD who notices sudden new distortion or rapid worsening of vision should treat this as an emergency and seek same-week ophthalmology review.
Dry AMD can convert to wet AMD at any stage. Any stage of dry AMD can turn into wet AMD — and wet AMD is always the more serious form requiring urgent treatment. This conversion can happen quickly. The Amsler Grid (see Section 04) is the standard home monitoring tool — any new wavy or distorted lines should prompt same-week eye care.
The Three Stages of AMD
Small or medium drusen are present under the retina. No retinal pigment changes. Vision is usually completely normal at this stage — most patients have no idea they have AMD until it is found at a routine eye exam. Annual dilated eye exams and lifestyle modification (stop smoking, healthy diet) are the interventions at this stage.
Large drusen and/or pigment abnormalities in the macula. Some patients notice mild blurriness, especially in low light. AREDS2 supplements are recommended at this stage for patients who meet the clinical criteria (large drusen in one or both eyes, or advanced AMD in one eye). Risk of progression to advanced AMD is significantly elevated.
Either geographic atrophy (late dry AMD — patches of RPE cells have died, leaving permanent photoreceptor loss) or wet AMD (choroidal neovascularisation with active leakage). Central vision is significantly impaired. Treatment with anti-VEGF injections for wet AMD can stabilise and sometimes partially recover vision. Geographic atrophy currently has very limited treatment options, though complement inhibitors (pegcetacoplan) were FDA-approved in 2023.
The Amsler Grid — Test Your Vision Right Now
The Amsler Grid is the standard home monitoring tool for AMD. It is a simple grid of straight horizontal and vertical lines with a central dot. In a healthy macula, the grid lines appear perfectly straight and evenly spaced. In AMD, the lines near the central area appear wavy, distorted, bent, or missing — a symptom called metamorphopsia.
Use the interactive grid below. Select Normal, Early AMD, or Advanced AMD to see what each stage looks like — then test your own eyes using the instructions.
Symptoms — What AMD Actually Feels Like
Early AMD has no symptoms. This is both the biggest challenge and the biggest opportunity — detecting it before vision loss begins allows for lifestyle changes and supplement therapy to slow progression.
As AMD advances, the symptoms follow a characteristic pattern:
- Blurred central vision — words on a page lose sharpness, faces become unclear, fine detail disappears. Glasses don't help because the issue is in the retina, not the lens.
- Metamorphopsia (wavy or distorted lines) — straight lines — door frames, ruled paper, tiles — appear wavy, curved, or bent. This is often the first symptom patients notice and should trigger urgent review.
- Central scotoma (blind spot) — a dark, blurry, or missing patch develops in the centre of vision. It may start small and expand over time as more macular tissue is lost.
- Reduced contrast sensitivity — difficulty distinguishing between similar shades of colour. Steps may be hard to see in low light; words on a grey background become illegible.
- Increased light adaptation time — longer to adjust when moving from bright to dim light. Particularly noticeable when entering dimly lit rooms from outside.
- Difficulty reading despite adequate glasses — AMD patients often go through multiple pairs of new glasses before the macular cause is identified.
"Age-related macular degeneration most commonly affects people older than 55 years. Visual prognosis varies, with advanced lesions leading to rapid, progressive loss of central vision and contrast sensitivity. Although AMD is not a life-threatening disease, reduced vision profoundly compromises quality of life and necessitates living assistance for many patients."
Risk Factors — What Raises Your Chances
Some AMD risk factors cannot be changed. Several can. The modifiable ones are genuinely important — the evidence for smoking cessation as a risk reduction strategy for AMD is strong and consistent.
Risk levels are relative — based on epidemiological data. Smoking is the single largest modifiable risk factor for AMD across all populations.
Treatment — What Works and What Doesn't
For dry AMD: AREDS2 supplements
The Age-Related Eye Disease Study 2 (AREDS2) — a landmark 5-year NIH-funded trial — found that a specific combination of supplements reduced the risk of progression to advanced AMD by approximately 25% in patients with intermediate AMD or advanced AMD in one eye. The AREDS2 formula contains:
Important about AREDS2 supplements: They only work for patients who already have intermediate or advanced AMD in one eye. They do not prevent AMD from developing in people who don't yet have it. The original AREDS formula contained beta-carotene, which significantly increases lung cancer risk in smokers — AREDS2 replaced it with lutein and zeaxanthin, making it safe for everyone.
For wet AMD: anti-VEGF injections
Wet AMD is treated with intravitreal injections — injections directly into the vitreous cavity of the eye — of drugs that block vascular endothelial growth factor (VEGF). VEGF is the protein driving the growth of the abnormal blood vessels. Blocking it stops the leakage and, in most patients, stabilises or even partially improves vision.
| Drug | Brand | Approved For | Dosing | Notes |
|---|---|---|---|---|
| Ranibizumab | Lucentis | Wet AMD (FDA 2006) | Monthly → extended | First approved anti-VEGF; extensively studied |
| Bevacizumab | Avastin (off-label) | Cancer (off-label AMD) | Monthly → extended | Widely used in India, Africa — lower cost; equivalent efficacy to ranibizumab in CATT trial |
| Aflibercept | Eylea | Wet AMD (FDA 2011) | Monthly × 3, then q8w | Less frequent dosing after loading phase; available in India |
| Faricimab | Vabysmo | Wet AMD (FDA 2022) | Monthly × 4, then up to q16w | Bi-specific (VEGF-A + Ang-2). Longest injection interval. Newest generation. |
| Pegcetacoplan | Syfovre | Geographic atrophy (FDA 2023) | Monthly or alternate-month | Complement inhibitor for dry AMD — first treatment for GA |
In India, anti-VEGF injections — particularly bevacizumab off-label — are used to combat the disease process and reduce the damaging effects of leaky abnormal blood vessels, and are able to effectively stabilise vision in many patients, with some patients actually improving visual acuity. Bevacizumab's lower cost (approximately 1/40th of branded ranibizumab) makes wet AMD treatment accessible across India and Sub-Saharan Africa in a way that would otherwise be impossible.
AMD and Cataract Surgery — What You Need to Know
Both AMD and cataract affect the over-60 population — they frequently coexist. The questions patients ask most often:
- "Can I have cataract surgery if I have AMD?" — Yes, in most cases. Removing a cataract improves the clarity needed for AMD monitoring and treatment. Ophthalmologists can better examine the retina through a clear lens, and anti-VEGF injection targeting is more precise.
- "Will cataract surgery make my AMD worse?" — There is no evidence that cataract surgery causes AMD to progress. Some older studies suggested a link, but this has not been confirmed in controlled trials.
- "Which IOL should I choose if I have AMD?" — This is critical. Standard monofocal IOLs are recommended for AMD patients. Premium IOLs — multifocal, trifocal, EDOF designs — rely on a healthy macula to provide the multiple focal points they are designed for. AMD compromises the macula, making these premium lenses unreliable. Your surgeon from Agaaz Ophthalmics' network can advise on the best IOL choice for your specific AMD severity.
- "Will my vision improve after cataract surgery if I have AMD?" — Possibly but not as dramatically as AMD-free patients. Cataract surgery removes one cause of blurred vision; AMD-related blurring remains. The visual outcome depends heavily on AMD severity — mild AMD with good foveal function can yield very satisfying outcomes; advanced AMD with foveal atrophy will have a more limited result.
Lifestyle and AMD — What Actually Helps
- Stop smoking — the single most impactful thing. Smoking doubles the risk of developing AMD and accelerates progression. The benefit of stopping is seen within years.
- Diet rich in lutein and zeaxanthin — dark leafy greens (kale, spinach, methi/fenugreek leaves, curry leaves), eggs, and orange and yellow vegetables. The macular pigment is composed of lutein and zeaxanthin, and dietary intake directly affects macular pigment density.
- Omega-3 fatty acids — oily fish (mackerel, sardines, tuna), flaxseed, walnuts. The AREDS2 trial tested omega-3 supplementation but found no additional benefit beyond the core formula; observational studies still suggest dietary omega-3 is protective.
- UV protection — quality sunglasses that block UVA and UVB outdoors. Particularly important in India, Africa, and the Middle East where UV index is high year-round.
- Blood pressure control — hypertension is associated with accelerated AMD progression. Controlling blood pressure with lifestyle and medication is protective for both cardiovascular and retinal health.
- Regular exercise — moderate aerobic exercise is associated with lower AMD risk in observational studies. Exercise improves systemic and retinal circulation.
- Annual dilated eye exams — AMD is often found before symptoms begin. Patients over 50 with any risk factors (family history, smoker, hypertensive) should have annual retinal examination.
Frequently Asked Questions
AMD Across Agaaz's Markets
AMD affects every region where Agaaz Ophthalmics operates — though prevalence, presentation, and access to care vary significantly.
- India: An estimated 8–12 million people in India have AMD, with incidence rising as the population ages. India performs over 7 million cataract surgeries per year — a significant proportion of these patients also have concurrent AMD. Bevacizumab (off-label) is the most widely used anti-VEGF in India due to cost. Tamil Nadu, Maharashtra, and Gujarat have the most active vitreoretinal surgical capacity.
- UAE and Saudi Arabia: Higher AMD rates than expected due to high UV exposure and smoking prevalence among men. Access to all anti-VEGF agents including faricimab. Agaaz exports surgical products to ophthalmology centres across the UAE.
- Nigeria and Kenya: AMD is significantly underdiagnosed due to limited retinal screening capacity and ophthalmologist density. Bevacizumab is the primary anti-VEGF where available. Need for IOL and vitreoretinal surgical supply is growing — where Agaaz products are reaching.
- South Africa: Better-developed retinal services in Cape Town, Johannesburg, and Durban. AMD prevalence increases in white South African population; rising in other populations as life expectancy increases.
- Philippines, Vietnam, Indonesia, Malaysia: Ageing populations with rising AMD burden. Ranibizumab and aflibercept are registered; bevacizumab widely used off-label. Retinal surgical training and infrastructure expanding rapidly.
Related Guides from Agaaz Ophthalmics
All published on Beyond Vision — ophthalmic education from Agaaz Ophthalmics.
Agaaz Ophthalmics manufactures intraocular lenses, RETSIL silicone oil, MOXGUARD intracameral moxifloxacin, and a complete range of cataract and vitreoretinal surgical products. View full portfolio →
The Short Version
- AMD is the most common cause of central vision loss in over-60s. It does not cause complete blindness — peripheral vision is usually preserved.
- 80–90% of cases are dry AMD — slow progressive degeneration with no reversal treatment. AREDS2 supplements reduce progression risk by 25% in appropriate patients.
- 10–20% are wet AMD — rapid onset, treatable with anti-VEGF injections (bevacizumab, ranibizumab, aflibercept, faricimab). Early treatment preserves vision.
- The Amsler Grid is the standard home monitoring tool. Test each eye separately weekly. Any new waviness = same-week eye care.
- Smoking doubles AMD risk — stopping is the single most important thing a patient can do.
- AMD and cataract frequently coexist. Cataract surgery is safe with AMD, but premium IOLs (multifocal, EDOF) are not recommended — monofocal IOLs are the correct choice.
- Annual dilated eye exams from age 50 — AMD is often found before symptoms. Early detection is the only chance to intervene before vision loss begins.
Clinical References
- Mitchell P, Liew G et al. Age-related macular degeneration. The Lancet. 2018;392(10153):1147–1159.
- Wong WL, Su X et al. Global prevalence of age-related macular degeneration. The Lancet Glob Health. 2014;2(2):e106–116. PubMed 24433433 →
- AREDS2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for AMD. JAMA. 2013;309(19):2005–2015. PubMed 23644932 →
- Mathis T, Kodjikian L. Age-Related Macular Degeneration: New Insights. J Clin Med. 2022;11(4):1064. PMC8878711 →
- National Eye Institute. Age-Related Macular Degeneration. nei.nih.gov →
- Fleckenstein M, Keenan TDL et al. Age-related macular degeneration. Nature Reviews Disease Primers. 2021;7(1):31.
- Martin DF et al. Ranibizumab and bevacizumab for neovascular AMD. NEJM. 2011;364:1897–1908. (CATT trial)
- Heier JS et al. Faricimab for neovascular AMD. The Lancet. 2022;399(10326):741–755.
- UAMS Health. Age-Related Macular Degeneration. Published May 2026. UAMS →
This article is for patient education only. It does not replace individual clinical advice from your ophthalmologist. AMD management should be guided by your treating physician based on your OCT findings, AMD stage, and overall health. Supplement recommendations require clinical assessment before starting.
Age-related macular
degeneration —
what is happening
to your central vision
AMD is the most common cause of vision loss in people over 60. It doesn't cause complete blindness — but it can take away your ability to read, drive, and recognise faces. Here is what you need to know.
When people describe their AMD diagnosis, they often say the same thing: "My vision went blurry but I thought it was just my glasses." AMD is deceptive. It starts in the peripheral retina, works its way inward slowly, and by the time the central vision goes, the disease has usually been present for years.
This guide is published by Agaaz Ophthalmics — an Indian manufacturer of ophthalmic surgical products used in the surgeries and procedures that treat eye disease. We write these guides because patients deserve to understand what is happening inside their eyes, not just receive a diagnosis they can't interpret.
AMD is the leading cause of irreversible central vision loss in people over 60 in high-income countries — and it is rising rapidly across India, the Middle East (UAE, Saudi Arabia), Sub-Saharan Africa (Nigeria, South Africa, Kenya), and Southeast Asia (Philippines, Indonesia, Malaysia) as populations age. Understanding it is the first step to managing it.
AMD does not cause complete blindness. Peripheral (side) vision is almost always preserved. What AMD takes is central vision — the sharp, straight-ahead vision needed to read, drive, and recognise faces. Most people with AMD can still see well enough to move around independently, but reading, fine detail work, and recognising faces becomes progressively difficult without support.
What Is Macular Degeneration — and What Is the Macula?
The macula is a small, highly specialised area at the very centre of the retina — roughly 5mm in diameter. Despite its size, it is responsible for all your sharp, detailed central vision. When you read a word, look at a face, or thread a needle, you are using your macula. It contains the highest density of cone photoreceptors of anywhere in the retina.
Age-related macular degeneration (AMD) is a progressive disease in which the macula deteriorates over time. The "age-related" part matters — it is the most important risk factor. AMD rarely occurs under 55, but affects approximately 10% of people over 75 and up to 30% of those over 85.
The disease typically begins with the accumulation of waste deposits under the retinal pigment epithelium (RPE) — the layer of cells that nourishes and maintains the photoreceptors. These deposits are called drusen. Small drusen are normal with ageing. Large or numerous drusen signal early AMD and indicate the eye is struggling to clear its waste products efficiently.
AMD vs cataract — the difference many patients confuse: Both cause blurry vision, but they are completely different diseases. A cataract is a clouding of the eye's lens — it is surgically curable. AMD is a disease of the retina — it cannot be cured, only slowed or stabilised. Some patients have both simultaneously. If you have AMD and need cataract surgery, see the dedicated section later in this guide.
Dry AMD vs Wet AMD — The Critical Difference
AMD exists in two forms — dry and wet — and the distinction matters enormously for prognosis and treatment.
Wet AMD develops when abnormal new blood vessels — a process called choroidal neovascularisation (CNV) — grow under the macula. These vessels are fragile. They leak fluid and blood into the retina, causing rapid, severe vision loss. Any patient with dry AMD who notices sudden new distortion or rapid worsening of vision should treat this as an emergency and seek same-week ophthalmology review.
Dry AMD can convert to wet AMD at any stage. Any stage of dry AMD can turn into wet AMD — and wet AMD is always the more serious form requiring urgent treatment. This conversion can happen quickly. The Amsler Grid (see Section 04) is the standard home monitoring tool — any new wavy or distorted lines should prompt same-week eye care.
The Three Stages of AMD
Small or medium drusen are present under the retina. No retinal pigment changes. Vision is usually completely normal at this stage — most patients have no idea they have AMD until it is found at a routine eye exam. Annual dilated eye exams and lifestyle modification (stop smoking, healthy diet) are the interventions at this stage.
Large drusen and/or pigment abnormalities in the macula. Some patients notice mild blurriness, especially in low light. AREDS2 supplements are recommended at this stage for patients who meet the clinical criteria (large drusen in one or both eyes, or advanced AMD in one eye). Risk of progression to advanced AMD is significantly elevated.
Either geographic atrophy (late dry AMD — patches of RPE cells have died, leaving permanent photoreceptor loss) or wet AMD (choroidal neovascularisation with active leakage). Central vision is significantly impaired. Treatment with anti-VEGF injections for wet AMD can stabilise and sometimes partially recover vision. Geographic atrophy currently has very limited treatment options, though complement inhibitors (pegcetacoplan) were FDA-approved in 2023.
The Amsler Grid — Test Your Vision Right Now
The Amsler Grid is the standard home monitoring tool for AMD. It is a simple grid of straight horizontal and vertical lines with a central dot. In a healthy macula, the grid lines appear perfectly straight and evenly spaced. In AMD, the lines near the central area appear wavy, distorted, bent, or missing — a symptom called metamorphopsia.
Use the interactive grid below. Select Normal, Early AMD, or Advanced AMD to see what each stage looks like — then test your own eyes using the instructions.
Symptoms — What AMD Actually Feels Like
Early AMD has no symptoms. This is both the biggest challenge and the biggest opportunity — detecting it before vision loss begins allows for lifestyle changes and supplement therapy to slow progression.
As AMD advances, the symptoms follow a characteristic pattern:
- Blurred central vision — words on a page lose sharpness, faces become unclear, fine detail disappears. Glasses don't help because the issue is in the retina, not the lens.
- Metamorphopsia (wavy or distorted lines) — straight lines — door frames, ruled paper, tiles — appear wavy, curved, or bent. This is often the first symptom patients notice and should trigger urgent review.
- Central scotoma (blind spot) — a dark, blurry, or missing patch develops in the centre of vision. It may start small and expand over time as more macular tissue is lost.
- Reduced contrast sensitivity — difficulty distinguishing between similar shades of colour. Steps may be hard to see in low light; words on a grey background become illegible.
- Increased light adaptation time — longer to adjust when moving from bright to dim light. Particularly noticeable when entering dimly lit rooms from outside.
- Difficulty reading despite adequate glasses — AMD patients often go through multiple pairs of new glasses before the macular cause is identified.
"Age-related macular degeneration most commonly affects people older than 55 years. Visual prognosis varies, with advanced lesions leading to rapid, progressive loss of central vision and contrast sensitivity. Although AMD is not a life-threatening disease, reduced vision profoundly compromises quality of life and necessitates living assistance for many patients."
Risk Factors — What Raises Your Chances
Some AMD risk factors cannot be changed. Several can. The modifiable ones are genuinely important — the evidence for smoking cessation as a risk reduction strategy for AMD is strong and consistent.
Risk levels are relative — based on epidemiological data. Smoking is the single largest modifiable risk factor for AMD across all populations.
Treatment — What Works and What Doesn't
For dry AMD: AREDS2 supplements
The Age-Related Eye Disease Study 2 (AREDS2) — a landmark 5-year NIH-funded trial — found that a specific combination of supplements reduced the risk of progression to advanced AMD by approximately 25% in patients with intermediate AMD or advanced AMD in one eye. The AREDS2 formula contains:
Important about AREDS2 supplements: They only work for patients who already have intermediate or advanced AMD in one eye. They do not prevent AMD from developing in people who don't yet have it. The original AREDS formula contained beta-carotene, which significantly increases lung cancer risk in smokers — AREDS2 replaced it with lutein and zeaxanthin, making it safe for everyone.
For wet AMD: anti-VEGF injections
Wet AMD is treated with intravitreal injections — injections directly into the vitreous cavity of the eye — of drugs that block vascular endothelial growth factor (VEGF). VEGF is the protein driving the growth of the abnormal blood vessels. Blocking it stops the leakage and, in most patients, stabilises or even partially improves vision.
| Drug | Brand | Approved For | Dosing | Notes |
|---|---|---|---|---|
| Ranibizumab | Lucentis | Wet AMD (FDA 2006) | Monthly → extended | First approved anti-VEGF; extensively studied |
| Bevacizumab | Avastin (off-label) | Cancer (off-label AMD) | Monthly → extended | Widely used in India, Africa — lower cost; equivalent efficacy to ranibizumab in CATT trial |
| Aflibercept | Eylea | Wet AMD (FDA 2011) | Monthly × 3, then q8w | Less frequent dosing after loading phase; available in India |
| Faricimab | Vabysmo | Wet AMD (FDA 2022) | Monthly × 4, then up to q16w | Bi-specific (VEGF-A + Ang-2). Longest injection interval. Newest generation. |
| Pegcetacoplan | Syfovre | Geographic atrophy (FDA 2023) | Monthly or alternate-month | Complement inhibitor for dry AMD — first treatment for GA |
In India, anti-VEGF injections — particularly bevacizumab off-label — are used to combat the disease process and reduce the damaging effects of leaky abnormal blood vessels, and are able to effectively stabilise vision in many patients, with some patients actually improving visual acuity. Bevacizumab's lower cost (approximately 1/40th of branded ranibizumab) makes wet AMD treatment accessible across India and Sub-Saharan Africa in a way that would otherwise be impossible.
AMD and Cataract Surgery — What You Need to Know
Both AMD and cataract affect the over-60 population — they frequently coexist. The questions patients ask most often:
- "Can I have cataract surgery if I have AMD?" — Yes, in most cases. Removing a cataract improves the clarity needed for AMD monitoring and treatment. Ophthalmologists can better examine the retina through a clear lens, and anti-VEGF injection targeting is more precise.
- "Will cataract surgery make my AMD worse?" — There is no evidence that cataract surgery causes AMD to progress. Some older studies suggested a link, but this has not been confirmed in controlled trials.
- "Which IOL should I choose if I have AMD?" — This is critical. Standard monofocal IOLs are recommended for AMD patients. Premium IOLs — multifocal, trifocal, EDOF designs — rely on a healthy macula to provide the multiple focal points they are designed for. AMD compromises the macula, making these premium lenses unreliable. Your surgeon from Agaaz Ophthalmics' network can advise on the best IOL choice for your specific AMD severity.
- "Will my vision improve after cataract surgery if I have AMD?" — Possibly but not as dramatically as AMD-free patients. Cataract surgery removes one cause of blurred vision; AMD-related blurring remains. The visual outcome depends heavily on AMD severity — mild AMD with good foveal function can yield very satisfying outcomes; advanced AMD with foveal atrophy will have a more limited result.
Lifestyle and AMD — What Actually Helps
- Stop smoking — the single most impactful thing. Smoking doubles the risk of developing AMD and accelerates progression. The benefit of stopping is seen within years.
- Diet rich in lutein and zeaxanthin — dark leafy greens (kale, spinach, methi/fenugreek leaves, curry leaves), eggs, and orange and yellow vegetables. The macular pigment is composed of lutein and zeaxanthin, and dietary intake directly affects macular pigment density.
- Omega-3 fatty acids — oily fish (mackerel, sardines, tuna), flaxseed, walnuts. The AREDS2 trial tested omega-3 supplementation but found no additional benefit beyond the core formula; observational studies still suggest dietary omega-3 is protective.
- UV protection — quality sunglasses that block UVA and UVB outdoors. Particularly important in India, Africa, and the Middle East where UV index is high year-round.
- Blood pressure control — hypertension is associated with accelerated AMD progression. Controlling blood pressure with lifestyle and medication is protective for both cardiovascular and retinal health.
- Regular exercise — moderate aerobic exercise is associated with lower AMD risk in observational studies. Exercise improves systemic and retinal circulation.
- Annual dilated eye exams — AMD is often found before symptoms begin. Patients over 50 with any risk factors (family history, smoker, hypertensive) should have annual retinal examination.
Frequently Asked Questions
AMD Across Agaaz's Markets
AMD affects every region where Agaaz Ophthalmics operates — though prevalence, presentation, and access to care vary significantly.
- India: An estimated 8–12 million people in India have AMD, with incidence rising as the population ages. India performs over 7 million cataract surgeries per year — a significant proportion of these patients also have concurrent AMD. Bevacizumab (off-label) is the most widely used anti-VEGF in India due to cost. Tamil Nadu, Maharashtra, and Gujarat have the most active vitreoretinal surgical capacity.
- UAE and Saudi Arabia: Higher AMD rates than expected due to high UV exposure and smoking prevalence among men. Access to all anti-VEGF agents including faricimab. Agaaz exports surgical products to ophthalmology centres across the UAE.
- Nigeria and Kenya: AMD is significantly underdiagnosed due to limited retinal screening capacity and ophthalmologist density. Bevacizumab is the primary anti-VEGF where available. Need for IOL and vitreoretinal surgical supply is growing — where Agaaz products are reaching.
- South Africa: Better-developed retinal services in Cape Town, Johannesburg, and Durban. AMD prevalence increases in white South African population; rising in other populations as life expectancy increases.
- Philippines, Vietnam, Indonesia, Malaysia: Ageing populations with rising AMD burden. Ranibizumab and aflibercept are registered; bevacizumab widely used off-label. Retinal surgical training and infrastructure expanding rapidly.
Related Guides from Agaaz Ophthalmics
All published on Beyond Vision — ophthalmic education from Agaaz Ophthalmics.
Agaaz Ophthalmics manufactures intraocular lenses, RETSIL silicone oil, MOXGUARD intracameral moxifloxacin, and a complete range of cataract and vitreoretinal surgical products. View full portfolio →
The Short Version
- AMD is the most common cause of central vision loss in over-60s. It does not cause complete blindness — peripheral vision is usually preserved.
- 80–90% of cases are dry AMD — slow progressive degeneration with no reversal treatment. AREDS2 supplements reduce progression risk by 25% in appropriate patients.
- 10–20% are wet AMD — rapid onset, treatable with anti-VEGF injections (bevacizumab, ranibizumab, aflibercept, faricimab). Early treatment preserves vision.
- The Amsler Grid is the standard home monitoring tool. Test each eye separately weekly. Any new waviness = same-week eye care.
- Smoking doubles AMD risk — stopping is the single most important thing a patient can do.
- AMD and cataract frequently coexist. Cataract surgery is safe with AMD, but premium IOLs (multifocal, EDOF) are not recommended — monofocal IOLs are the correct choice.
- Annual dilated eye exams from age 50 — AMD is often found before symptoms. Early detection is the only chance to intervene before vision loss begins.
Clinical References
- Mitchell P, Liew G et al. Age-related macular degeneration. The Lancet. 2018;392(10153):1147–1159.
- Wong WL, Su X et al. Global prevalence of age-related macular degeneration. The Lancet Glob Health. 2014;2(2):e106–116. PubMed 24433433 →
- AREDS2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for AMD. JAMA. 2013;309(19):2005–2015. PubMed 23644932 →
- Mathis T, Kodjikian L. Age-Related Macular Degeneration: New Insights. J Clin Med. 2022;11(4):1064. PMC8878711 →
- National Eye Institute. Age-Related Macular Degeneration. nei.nih.gov →
- Fleckenstein M, Keenan TDL et al. Age-related macular degeneration. Nature Reviews Disease Primers. 2021;7(1):31.
- Martin DF et al. Ranibizumab and bevacizumab for neovascular AMD. NEJM. 2011;364:1897–1908. (CATT trial)
- Heier JS et al. Faricimab for neovascular AMD. The Lancet. 2022;399(10326):741–755.
- UAMS Health. Age-Related Macular Degeneration. Published May 2026. UAMS →
This article is for patient education only. It does not replace individual clinical advice from your ophthalmologist. AMD management should be guided by your treating physician based on your OCT findings, AMD stage, and overall health. Supplement recommendations require clinical assessment before starting.
Start writing here...
Age-Related Macular Degeneration (AMD) — Symptoms, Stages & Treatment 2026